vinorelbine tartrate / Generic mfg. 
Welcome,         Profile    Billing    Logout  

183 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vinorelbine tartrate / Generic mfg.
NCT02977169: To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Recruiting
2
300
RoW
PORT, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Shanghai Chest Hospital
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
12/21
12/21
NCT03854617: A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

Not yet recruiting
2
172
NA
Oral NVB Metronomic, Oral Navelbine Metronomic, Oral NVB Weekly, Oral Navelbine Weekly
Chinese Academy of Medical Sciences
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
12/21
12/25
NCT04265274: Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Withdrawn
2
28
Europe
Disulfiram, Antabus, Vinorelbin, Navelbine, Cisplatin, Copper
National Cancer Institute, Slovakia
Metastatic Breast Cancer
01/22
01/23
RIGHT Choice, NCT03839823: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Completed
2
223
RoW
Docetaxel / Capecitabine, Combination chemotherapy group., The chemotherapy regimen will be decided by the treating physician., Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine, Ribociclib, Endocrine treatment arm:, NSAI + goserelin+ ribociclib, Letrozole OR Anastrozole, Goserelin
Novartis Pharmaceuticals
Breast Cancer
04/22
05/23
ChiCTR2000036983: Evaluation of the efficacy and safety of Vinorelbine soft capsules combined with Anlotinib Hydrochloride in the treatment of advanced non-small cell lung cancer in elderly patients: a single-arm, multi-center Phase II clinical study

Recruiting
2
30
 
Anlotinib hydrochloride capsule -10 mg -oral administration daily for two weeks, Q3W; Vinorelbine soft capsule -30 mg -Oral administration every Monday, Wednesday, Friday
Shulan (Hangzhou) Hospital; Shulan (Hangzhou) Hospital, Shulan (Hangzhou) Hospital
advanced non-small cell lung cancer
 
 
2021-002561-18: Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic breast cancer “TrasTUCAN Study” Estudio fase 2 de un solo brazo sobre la eficacia y la seguridad de la combinación de trastuzumab, TUCAtinib y viNorelbina en pacientes con cáncer de mama localmente avanzado no resecable o metastásico HER2-positivo «Estudio TrasTUCAN

Ongoing
2
49
Europe
Film-coated tablet, TUKYSA
GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama), SEAGEN Inc
Non-resectable locally advanced or metastatic HER2-positive breast cancer. Cáncer de mama irresecable localmente avanzado o metastásico HER2-positivo., Non-resectable locally advanced or metastatic HER2-positive breast cancer. Cáncer de mama irresecable localmente avanzado o metastásico HER2-positivo., Diseases [C] - Cancer [C04]
 
 
DIPG, NCT03620032: Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses

Active, not recruiting
2
54
Europe
Nimotuzumab, humanized therapeutic monoclonal antibody, Vinorelbine, Chemotherapy, Radiotherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, University of Roma La Sapienza, Johannes Gutenberg University Mainz, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Wuerzburg University Hospital
Diffuse Intrinsic Pontine Glioma
11/22
11/24
SAFIR02_Breast, NCT02299999: - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting
2
1460
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736
UNICANCER, Fondation ARC, AstraZeneca
Metastatic Breast Cancer
12/22
12/24
NCT02607215: Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

Recruiting
2
84
RoW
Vinorelbine, NVB, DDP
Fudan University
Metastatic Breast Cancer
12/22
12/22
NCT03932526: Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Not yet recruiting
2
184
NA
Vinorelbine + placebo, AiTan+ placebo, Vinorelbine + Apatinib, Navelbine+AiTan
Liaoning Tumor Hospital & Institute
Triple-negative Breast Cancer
12/22
06/23
DURATION, NCT03345810 / 2016-003963-20: Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC

Completed
2
200
Europe
Durvalumab, MEDI4736, Vinorelbine, Gemcitabine, nab-Paclitaxel, Abraxane, Carboplatin
AIO-Studien-gGmbH, AstraZeneca, Celgene
Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Lung Adenocarcinoma Metastatic, Large Cell Lung Carcinoma Metastatic
12/22
12/22
NCC2167, NCT04389073: Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Recruiting
2
138
RoW
Vinorelbine 40mg, Toripalimab 240mg, JS001, Bevacizumab 5 mg/kg, Cyclophosphamide 50 mg, Capecitabine 500Mg Oral Tablet, Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Huanxing Cancer Hospital
Metastatic Breast Cancer
12/22
12/23
NCT04745975: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Recruiting
2
100
RoW
Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Fudan University
Triple Negative Breast Cancer
01/23
01/23
NCT04963595: Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Not yet recruiting
2
100
NA
Pyrotinib, Vinorelbine, Inetetamab
Zhiyong Yu
Metastatic Breast Cancer
01/23
07/24
MOCCCA, NCT03442673: Chemotherapy and G-CSF for Mobilization

Active, not recruiting
2
137
Europe
Vinorelbine, Gemcitabine, G-CSF
University Hospital Inselspital, Berne
Multiple Myeloma
02/23
05/24
2022-002582-15: Phase II Study mit Neratinib and Trastuzumab with or without Vinorelbine per mouth in patients with pretreated metastatic Her2- positive breast cancer Phase II Study mit Neratinib and Trastuzumab with or without Vinorelbine per mouth in patients with pretreated metastatic Her2- positive breast cancer

Ongoing
2
65
Europe
Neratinib, Navelbine, PRD7433212, L01CA04, Film-coated tablet, Capsule, Nerlynx, Navelbine
Medical University Graz, Pierre Fabre
Patients with histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive metastatic breast cancer (mBC) pretreated with trastuzumab, pertuzumab, and/or trastuzumab emtansine (T-DM1) and/ or T-DXd and/or tucatinib Patientinnen mit histologisch bestätigten Human Epidermen Wachstumsfaktor Rezeptor 2 (Her2) positiven metasierten Brustkrebserkrankung, vorbehandelt mit Trastuzumab, Pertuzumab und/ oder Trastuzumab Emtansine (T-DM1) und/ oder Trastuzumab Deruxtecan und/ oder Tucatinib, Patients with Her2 positive metastatic breast cancer who were pretreted with 2-4 lines of previous treatment Patientinnen mit Her2 positiven metastasierten Brustkrebserkrankung die mit 2-4 Therapielinien vorbehandelt wurden, Diseases [C] - Cancer [C04]
 
 
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
NCT04605575: Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Recruiting
2
208
RoW
Pyrotinib 320mg + Vinorelbine, Pyrotinib 400mg + Vinorelbine, Pyrotinib plus Vinorelbine
Sun Yat-sen University
Breast Cancer, Pyrotinib, Breast Diseases, Vinorelbine, HER2-positive Breast Cancer
08/23
12/23
ChiCTR2000035964: A multicenter, single-arm, phase II clinical trial of Apatinib in combination with Vinorelbine as second line treatment for patients with advanced triple-negative breast cancer

Not yet recruiting
2
52
 
Apatinib in combination with Vinorelbine
The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of SYSU, CSCO
Breast cancer
 
 
NCT04681911: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Recruiting
2
71
RoW
Inetetamab, Pyrotinib, Capecitabine, xeloda or other names, Gemcitabine, Gemzar or other names, Vinorelbine, Navelbine or other names, Carboplatin, Paraplatin or other names, Albumin paclitaxel, Abraxane or other names, Eribulin, Halaven
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
09/23
09/24
VinCaT, NCT00431704 / 2006-003994-28: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer

Active, not recruiting
2
39
Europe
vinorelbine, carboplatin, trastuzumab
National Cancer Institute, Naples
Metastatic Breast Cancer
12/23
12/23
ATREZZO, NCT04759248 / 2020-000245-13: Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Recruiting
2
55
Europe
Atezolizumab + Trastuzumab + Vinorelbine
SOLTI Breast Cancer Research Group, Roche Pharma AG
Breast Cancer
12/24
01/25
VEX, NCT04304352: Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients

Recruiting
2
162
Europe
Vinorelbine, Metronomic Vinorelbine, Capecitabine, Metronomic Capecitabine, Cyclophosphamide, Metronomic Cyclophosphamide
European Institute of Oncology
Advanced Breast Cancer
12/23
12/23
MCLA-128-CL02, NCT03321981 / 2017-002821-39: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Completed
2
105
Europe, US
Zenocutuzumab, MCLA-128, Trastuzumab, Herceptin, Vinorelbine, Navelbine, vinorelbine tartrate, Endocrine therapy, fulvestrant, exemestane, letrozole, anastrazole
Merus N.V.
Breast Cancer Metastatic
10/22
07/23
NCT05603013: Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Not yet recruiting
2
45
RoW
Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, IL-2
Second Affiliated Hospital of Soochow University
Carcinoma, Non-Small-Cell Lung, Carcinoma Breast
01/24
10/24
NCT06244368: GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Recruiting
2
115
RoW
GVM±R regimen
Qiu Lugui
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
06/25
06/27
NCT06229067: Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Not yet recruiting
2
182
NA
Adebrelimab, Vinorelbine, Cyclophosphamide (tablet), Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Triple Negative Breast Cancer
01/25
01/27
NCT04848454: Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Recruiting
2
30
RoW
Camrelizumab with vinorelbine and cisplatin
Peking University First Hospital
HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response, Immunotherapy, Vinorelbine, Cisplatin
02/24
12/24
ChiCTR2300069004: A Controlled, Phase II Study of Anlotinib vs Placebo Combination with Vinorelbine for the Treatment of HER2- Advanced Breast Cancer

Not yet recruiting
2
134
 
anlotinib plus vinorelbine ;vinorelbine
Henan Cancer Hospital; Henan Cancer Hospital, Self-finance
Breast cancer
 
 
NCT06355024: Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Not yet recruiting
2
10
NA
Inosine, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Fudan University
Triple-negative Breast Cancer
12/24
01/25
NCT06355037: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Not yet recruiting
2
10
NA
Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Fudan University
Triple-negative Breast Cancer
12/24
01/25
NCT06377566: A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting
2
71
US
Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Pembrolizumab, Gemcitabine, Vinorelbine, FDG-PET/CT scan
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Hodgkin Lymphoma
04/27
04/27
NCT04922008: Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

Not yet recruiting
2
356
NA
capecitabine and trastuzumab, vinorelbine and trastuzumab
Fudan University
Breast Cancer
06/24
06/26
ChiCTR2100047650: single-arm, single-center clinical trial of pyrotinib in combination with trastuzumab and vinorelbine neoadjuvant therapy for HER2-positive early or locally advanced breast cancer poor response to docetaxel + carboplatin + trastuzumab + pertuzumab

Not yet recruiting
2
28
 
Pyrotinib tablets: 400mg, QD, P.O., Q3W, a total of 6 cycles.; Trastuzumab: Trastuzumab: load dose of 8mg/kg for the first cycle and 6mg/kg for the subsequent cycle , IVGTT, D1, Q3W, a total of 6 cycles. Vinorelbine: 25mg/m2, d1, d8, Q3W, a total of 6 cycles.
Breast Oncology Center, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, Initiated by the researcher self
Breast cancer
 
 
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
69
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/24
08/24
NCT05296577: Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Recruiting
2
134
RoW
anlotinib and vinorelbine, AL3818 and vinorelbine, Vinorelbine injection, vinorelbine
Henan Cancer Hospital
Breast Cancer
09/24
12/24
NCT03443128: Vinorelbine for Recurrent ALCL-2017

Recruiting
2
20
RoW
Vinorelbine
Children's Cancer Group, China
Anaplastic Large Cell Lymphoma, Vinorelbine
12/24
09/25
NCT04922658: Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Recruiting
2
60
RoW
Surufatinib, Surufatinib Plus Vinorelbine
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Advanced Non-Small Cell Lung Cancer
12/24
06/25
NCT04143906: Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Not yet recruiting
2
200
NA
Vinorelbine, Gemcitabine, Carboplatin
Shandong Cancer Hospital and Institute
Metastatic Breast Cancer
12/24
12/24
ChiCTR2200057029: Multicenter clinical study of the efficacy and safety of Vinorelbine plus PD-1/PD-L1 inhibitor as maintenance therapy after first-line platinum chemotherapy for advanced lung squamous cell carcinoma

Not yet recruiting
2
93
 
Vinorelbine capsules +PD-1/PD-L1 inhibitor
The Seventh Affiliated Hospital of Sun Yat-Sen University; The Seventh Affiliated Hospital of Sun Yat-Sen University, Project 735, the Seventh Affiliated Hospital of Sun Yat-sen University
lung cancer
 
 
NCT05660993: Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
50
RoW
Nivolumab
National Research Center for Hematology, Russia
Hodgkin Lymphoma
03/25
03/25
ChiCTR2200058432: Phase II clinical study to evaluate the efficacy and safety of third generation EGFR-TKI combined with navelbine soft capsule metronotherapy in first-line treatment of patients with advanced NSCLC with EGFR mutation

Not yet recruiting
2
55
 
third generation EGFR - TKI+navelbine
First Affiliated Hospital of Soochow University; First Affiliated Hospital of Soochow University, self-finance
advanced NSCLC with EGFR mutation
 
 
NCT04624984: PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Recruiting
2
42
RoW
PD-1 inhibitor, PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
Sun Yat-sen University
Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma
04/25
04/25
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/26
05/26
BRIDGE, NCT04765709: Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

Active, not recruiting
2
10
Europe
durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed), Durvalumab plus radiotherapy, durvalumab
Mario Negri Institute for Pharmacological Research, AstraZeneca, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Non-small Cell Lung Cancer Stage III
06/26
06/26
NCT05826964: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Recruiting
2
500
US
AI+CDK4/6i, Aromatase Inhibitor (AI) + Cyclin dependent kinase 4 and 6 inhibitor (CDK4/6i), Anastrozole, Letrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib, SERD+CDK4/6i, Selective Estrogen Receptor Degrader (SERD) + CDK4/6i, Fulvestrant, mTOR inhibitor + AI, Mammalian target of rapamycin (mTOR) inhibitor + Aromatase Inhibitor (AI), Everolimus, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, Tamoxifen, PI3K inhibitor + SERD, Phosphoinositide 3-kinase (PI3K) inhibitor + SERD, Alpelisib, PI3K inhibitor + AI, Chemotherapy, Taxane, Eribulin, Capecitabine, Vinorelbine, Oral SERD, Elacestrant
University of Miami
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
07/26
07/29
TrasTUCAN, NCT05583110 / 2021-002561-18: Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Recruiting
2
49
Europe
Tucatinib, Tukysa, Trastuzumab, Herceptin, Vinorelbine, Navelbine
Spanish Breast Cancer Research Group, Seagen Inc.
HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma
08/26
08/26
NCT04388839: Evolutionary Therapy for Rhabdomyosarcoma

Recruiting
2
28
US
Vincristine, Cyclophosphamide, Vinorelbine, Navelbine, Actinomycin D, Cosmegen, Cyclophosphamide Pill
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Rhabdomyosarcoma
12/26
12/27
ORIENTA, NCT06102824: Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting
2
252
RoW
Organoid-guided treatment, Taxane, Abraxane, Lipusu, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine, Eribulin, Halaven, Anthracycline, Doxil, Lipodox, Carboplatin, Paraplatin, Utidelone, UTD1, Trastuzumab deruxtecan, Enhertu, Sacituzumab govitecan, Trodelvy
Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Shantou Central Hospital
HER2-negative Breast Cancer, Advanced Breast Cancer
06/27
06/28
2004-000602-44: Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado

Ongoing
1/2
63
Europe
Navelbine cápsulas blandas, Xeloda, NA, Navebine Cápsulas Blandas, Xeloda 500, 100 mg, Navebine Cápsulas Blandas, Xeloda 500, 100 mg
Pierre Fabre Ibérica, S.A.
Advanced breast cancer (metastatic)
 
 
SORT, ChiCTR-IPR-14005682: Clinical observation and efficacy predictors of the combined use of S1 and oxaliplatin in treating metastatic triple-negative breast cancer

Recruiting
1/2
60
 
Oxaliplatin 130mg/m2 D1, S-1 50mg/m2, b.i.d. D1-14, repeated every 3 weeks ;Gemcitabine 1000mg/m2 Vinorelbine 25mg/m2 D1, D8, repeated every 3 weeks
Breast Disease Center, ChongQing Tumer Hospital; None, Chongqing Health and Family Planning Commission
metastatic triple-negative breast cancer
 
 
2019-001972-12: A phase 1b/2 study on the safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors and advanced breast cancer

Not yet recruiting
1/2
65
Europe
disulfiram, vinorelbine, Effervescent tablet, Concentrate for solution for infusion
Department of Oncology, Herlev & Gentofte Hospital, Danish Cancer Society, Neye Fond
in phase 1b part: advanced and/or treatment refractory solid malignancies in phase 2 part : advanced or metastatic HER2-negative breast cancer, in phase 1b part: advanced solid tumors in phase 2 part: advanced breast cancer, Diseases [C] - Cancer [C04]
 
 
2019-004987-23: RASTRIC-trial: investigating the safety and efficacy of a new three drug treatment combination for RAS-mutated metastastic colorectal cancer. RASTRIC-studie: onderzoek naar de veiligheid en effectiviteit van een nieuwe behandeling met drie middelen voor RAS-gemuteerde uitgezaaide dikke darmkanker.

Not yet recruiting
1/2
50
Europe
Mektovi, Tyverb, vinorelbine, EMEA/H/C/004579, EMEA/H/C/000795, RVG 35294, Film-coated tablet, Concentrate and solvent for solution for infusion, Mektovi, Tyverb, vinorelbine
UMC Utrecht, ONCODE institute, UMC Utrecht
colorectal cancer colorectaal carcinoom, colorectal cancer dikkedarmkanker, Diseases [C] - Cancer [C04]
 
 
NCT06202261: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Recruiting
1/2
154
RoW
TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine tablets, Vinorelbine tartrate injection, Eribulin mesylate injection, gemcitabine hydrochloride for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
12/26
10/27
2019-101826, NCT04896320: Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

Withdrawn
1/2
40
US
Tucatinib
Providence Health & Services, Seagen Inc.
Breast Cancer Stage IV
06/23
06/23
NCT04145349 / 2018-004242-42: CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Active, not recruiting
1/2
34
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine
Eli Lilly and Company
Desmoplastic Small Round Cell Tumor
06/24
10/24
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
140
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
05/25
12/28
FaR-RMS, NCT04625907 / 2018-000515-24: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting
1/2
1672
Europe, RoW
Irinotecan, Actinomycin D, Dactinomycin, Doxorubicin, Ifosfamide, Vincristine, Vinorelbine, Cyclophosphamide, Temozolomide, radiotherapy, Regorafenib
University of Birmingham
Rhabdomyosarcoma
06/30
06/30
NCT06023641: Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Recruiting
1/2
100
US
Vincristine, Oncovin, Dactinomycin, (actinomycin-D), Cyclophosphamide, Cytoxan®., Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, (Onivyde®), Vinorelbine, Navelbine, Temozolomide, Temodar, Filgrastim, peg-filgrastim, Neupogen
St. Jude Children's Research Hospital
Rhabdomyosarcoma
10/34
10/37
ChiCTR-IPR-15005856: Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine and vinorelbine solution in a clinical study of patients with non-small cell lung cancer

Recruiting
1
24
 
1st period, reference formulation 30mg/m2, 2nd period test formulation 30mg/m2 ;1st period test formulation 30mg/m2, 2nd period reference formulation 30mg/m2
The first affiliated hospital, School of Medicine, Zhejiang University; Hangzhou Mingsheng Pharmaceutical Company, Hangzhou Mingsheng Pharmaceutical Company
Non-small cell lung cancer
 
 
ChiCTR-TRC-12003744: Multicenter, randomized, double-blind, placebo, parallel-group phase III clinical studies of recombinant human (rh) Apo2L/TRAIL in combination with vinorelbine and cispatin （NP） in patients with advanced NSCLC

Completed
1
480
 
NP+rh-Apo2L ;NP+placebo
General Hospital of Nanjing military region, Fuzhou, PLA; Shanghai GeBaiDe Bio-technology Co., Ltd, self-financing
NSCLC
 
 
ACTRN12613000423718: A phase I study of vinorelbine, cyclophosphamide and Rapamycin for recurrent malignancies in children

Completed
1
48
 
Australian New Zealand Childrens Haematology Oncology Group
recurrent malignancies
 
 
NCT05299164: GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Active, not recruiting
1
18
RoW
Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level 2, Liposomal Mitoxantrone Hydrochloride dose level 3, Liposomal Mitoxantrone Hydrochloride dose level 4
Institute of Hematology & Blood Diseases Hospital, China, CSPC Ouyi Pharmaceutical Co., Ltd.
Non Hodgkin Lymphoma
12/23
12/25
ARCADIAN, NCT04648033: Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC

Completed
1
21
Europe
Atovaquone Oral Suspension, Wellvone, Standard of care chemotherapy, Cisplatin, Vinorelbine, Standard of care radiotherapy
University of Oxford, Cancer Research UK, National Institute for Health Research, United Kingdom, NHS Lothian, Oxford University Hospitals NHS Trust, NHS Research Scotland, Guy's and St Thomas' NHS Foundation Trust
Locally Advanced Non-Small Cell Lung Cancer
10/23
10/23
NCT06137651: Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Withdrawn
1
34
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Resection, Surgical Resection, Trotabresib, 4-(2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl)-2-methylisoquinolin-1-one, BET Inhibitor CC-90010, CC 90010, CC-90010, CC90010, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine
Northwestern University, National Cancer Institute (NCI)
Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges
03/24
03/24
NCT04299113: Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Recruiting
1
38
US
Vinorelbine, 3'',4''-Didehydro-4''-deoxy-C''-norvincaleukoblastine, 5''-Nor-Anhydrovinblastine, 71486-22-1, Dihydroxydeoxynorvinkaleukoblastine, nor-5''-Anhydrovinblastine, vinorelbine, VINORELBINE, Mocetinostat, 726169-73-9, Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-, MG-0103, MGCD0103, MGCD0103, N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
Jonsson Comprehensive Cancer Center, Mirati Therapeutics Inc., Phase One Foundation
Rhabdomyosarcoma
05/25
05/26
ZWI-ZW25-101, NCT02892123: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Active, not recruiting
1
279
Canada, US, RoW
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Jazz Pharmaceuticals
HER2-expressing Cancers
06/24
07/24
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26
ChiCTR-BDN-16009613: Molecular diagnosis of BRAF-like colon cancer and the modeling of the humanized PDX

Not yet recruiting
N/A
30
 
Vinorelbine ;PD-1 ;Vinorelbine+PD-1 ; Vinorelbine ;PD-1 ;Vinorelbine+PD-1
Renji Hospital, School of Medicine, Shanghai Jiaotong University; Renji Hospital, School of Medicine, Shanghai Jiaotong University, hospital development center
colon cancer
 
 
ChiCTR1900024003: Study for the efficacy and tolerance of metronome chemotherapy combined with a generation of egfr-tki in first-line treatment of advanced egfr-positive NSCLC

Not yet recruiting
N/A
30
 
Lcotinib combined with Vinorelbine
Fujian Provincial Cancer Hospital; Level of the institution：, self-raised
Lung adenocarcinoma with EGFR mutation
 
 
NCT02985658: Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

No Longer Available
N/A
US
Veliparib, ABT-888, Cisplatin, Platinol-AQ, Platinol, Vinorelbine, Navelbine
University of Washington, AbbVie
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
 
 
ChiCTR2100042535: Objective to evaluate a prospective, single arm, single center clinical study of vinorelbine loaded callispheres microspheres in the treatment of stage III - IV non-small cell lung cancer with obstructive atelectasis

Recruiting
N/A
20
 
CalliSpheres drug-eluting beads bronchial arterial chemoembolization
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Jiangsu Hengrui Medicine Co.,Ltd.
Lung cancer
 
 
ChiCTR2000034449: Gefitinib combined with vinorelbine soft capsules vs gefitinib monotherapy in the treatment of stage IIIB-IV NSCLC patients with EGFR-sensitive mutation

Recruiting
N/A
50
 
gefitinib combined with vinorelbine soft capsule ;gefitinib monotherapy
National Cancer Center /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.; National Cancer Center /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College., Beijing Medical Award Foundation
NSCLC
 
 
ChiCTR2100043079: Observational study of R2 chop (lenalidomide, rituximab, cyclophosphamide, doxorubicin, vindesine / vinorelbine and prednisone) in the first-line treatment of high-risk / high-risk DLBCL

Recruiting
N/A
100
 
Lenalidomide, 25mg, orally on day 1-14
The First Affiliated Hospital of Kunming Medical University; The First Affiliated Hospital of Kunming Medical University, manufactor
DLBCL
 
 
NCT06373744: Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients

Completed
N/A
597
RoW
cyclophosphamide , methotrexate , vinorelbine ,capecitabine
Sun Yat-sen University
Breast Cancer
01/24
01/24
NCT06310915: Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Recruiting
N/A
30
RoW
Navelbine oral,Pembrolizumab
Guangzhou Institute of Respiratory Disease
Non-small Cell Lung Cancer Stage IIIB/IV
03/25
05/25
ChiCTR2100043105: Treatment of physician's choice, Pyrotinib combined with Trastuzumab among HER 2 positive breast cancer who are no response after receiving the neoadjuvant Trastuzumab and Pertuzumab regimens: a single-arm, multi-centre clinical exploratory study

Recruiting
N/A
30
 
Pyrotinib, Capecitabine or Vinorelbine or Eribulin, combined with Trastuzumab
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Breast cancer
 
 
NCT06211881: Chi-GVM Regimen for the Treatment of R/R PTCL

Recruiting
N/A
50
RoW
Chi-GVM, Chidamide Combined With Gemcitabine, Vinorelbine, and Mitoxantrone Hydrochloride Liposome
The First Affiliated Hospital with Nanjing Medical University
Relapsed/Refractory Peripheral T-cell Lymphoma
09/25
09/25
NCT05764941: Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Recruiting
N/A
100
RoW
Inetetamab, Pyrotinib, Vinorelbine
The First Affiliated Hospital with Nanjing Medical University
Breast Neoplasms
03/24
03/24
NCT06451302: Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study

Active, not recruiting
N/A
100
RoW
cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide, vinorelbine
Yizhuo Zhang
Ewing Sarcoma, Risk Stratification
05/27
12/27
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated
N/A
5
US
Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
02/24
02/24
HER2-VIP, NCT05856383: Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Recruiting
N/A
100
RoW
Inetetamab Combined With Pyrotinib and Vinorelbine
Zhejiang Cancer Hospital
HER2-positive Advanced Breast Cancer
12/27
12/27
NARLAL2, NCT02354274: Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®

Recruiting
N/A
330
Europe
Escalated: Inhomogeneous dose plan, Standard: Homogeneous dose plan
Olfred Hansen, Odense University Hospital, Aarhus University Hospital, Rigshospitalet, Denmark, Vejle Hospital, Naestved Hospital, Aalborg University Hospital, Herlev Hospital
NSCLC
10/29
10/29
 

Download Options